rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

GTCB los ?

27.049 Posts
Pagina: «« 1 ... 1340 1341 1342 1343 1344 ... 1353 »» | Laatste | Omlaag ↓
  2. [verwijderd] 21 juni 2006 19:06

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    De Dow en Nas staan ook flink in de plus....de komende dagen gaat het weer even flink omhoog denk ik...zou mooi zijn als GTCB op $2 staat alvorens de definitieve goedkeuring bekend wordt gemaakt.

    Ik heb natuurlijk niet voor niets 25K gekocht de laatste weken.
  3. [verwijderd] 21 juni 2006 20:07

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Yahoe schreef:

    De Dow en Nas staan ook flink in de plus....de komende dagen gaat het weer even flink omhoog denk ik...zou mooi zijn als GTCB op $2 staat alvorens de definitieve goedkeuring bekend wordt gemaakt.

    Ik heb natuurlijk niet voor niets 25K gekocht de laatste weken.
    bijgekocht op 1,49 en 1,53
    eerder op 1,42

    heb weer redelijke pluk
  4. [verwijderd] 21 juni 2006 20:15

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Bij deze welkom terug
    crackedtooth

    Een Amerikaanse belegger,
    schrijft

    Competing Rebalancing effects...
    by: croumagnon 06/21/06 02:03 pm
    Msg: 34016 of 34017

    Besides the Russell rebalancing by June 30, which is probably more of a negative than a positive for GTCB, we also have the window dressing for end of quarter rebalancing by the funds, which should be a huge positive for GTCB.

    If you look at the chart of GTCB for the last quarter, you will see that we have moved from $1 to $1.5. That means that we have gained 50% in the last three month. This is a huge enticement for fund mangers that want to look like winners in their quarterly window dressing especially that the future for GTCB even looks brighter. I know that there are not a lot of funds involved with stocks below $5 but still this should be a big positive that may in fact be a much bigger effect than the Russell rebalancing.

    Again, I claim that soon we will not be able to buy GTCB below $2, and soon maybe a matter of two weeks...


    quote:

    crackedtooth schreef:

    [quote=Yahoe]
    De Dow en Nas staan ook flink in de plus....de komende dagen gaat het weer even flink omhoog denk ik...zou mooi zijn als GTCB op $2 staat alvorens de definitieve goedkeuring bekend wordt gemaakt.

    Ik heb natuurlijk niet voor niets 25K gekocht de laatste weken.
    [/quote]

    bijgekocht op 1,49 en 1,53
    eerder op 1,42

    heb weer redelijke pluk
  5. [verwijderd] 21 juni 2006 20:17

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    had eerder al op 1,33 gekocht weer
    en na afkeuring 1,32 verkocht..

    daarna op 1,47 eruit..

    en op 1,42 erin

    nu dus bijgekocht
    blijf erbij dat dilutie minder fijn is
    maar bij definitieve goedkeuring zeker spike

    verwacht op korte termijn iets meer van die andere kandidaat
    maar gtcb zeker goede investering nu

    fnsr net omhoog nadat ik pluk weggedaan had gister wachtend op definitieve bodem...bah
  9. [verwijderd] 21 juni 2006 21:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    [quote=lagharrys]
    Hij moet onder de 1.50 blijven nl!
    [/quote]

    yep..rustig plukjes blijven kopen
    Ik koop alleen nog onder de 1.40 als ie daar ooit nog komt(je weet het nooit). Ik heb er genoeg nu!
  14. [verwijderd] 21 juni 2006 22:02

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    lagharrys schreef:

    [quote=crackedtooth]
    [quote=lagharrys]
    Hij moet onder de 1.50 blijven nl!
    [/quote]

    yep..rustig plukjes blijven kopen
    [/quote]

    Ik koop alleen nog onder de 1.40 als ie daar ooit nog komt(je weet het nooit). Ik heb er genoeg nu!
    ik heb veel meer insm
    net weer aan accumuleren
    nu 13k gtcb slechts
    ik zie wel wat hij doet
  16. [verwijderd] 22 juni 2006 09:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Van Pharming forum

    By Kirsty Barnes

    22/06/2006 - The world’s first drug made from a genetically engineered goat has been given the thumbs up in Europe after being initially rejected in February. The decision has reopened the door for “pharming,” where transgenic animals or plants are used to make drugs.

    The European Medicines Agency's (EMEA's) review process was the first regulatory examination of a transgenically produced therapeutic protein anywhere in the world, representing the first real sign that the many transgenic drugs in the biopharma pipeline can gain acceptance from regulators.

    "Our company has taken a simple concept and turned it into a practical reality and now the setbacks and challenges were worth it," Thomas Newberry, a spokesperson from GTC Biotherapeutics, developers of the drug, told In-PharmaTechnologist.com.

    The news is welcomed by the many biotech firms who were shaken by the EMEA's initial decision to reject the drug, having invested hundreds of millions of dollars in transgenic technology.

    Be it recombinant proteins in milk, polyclonal antibodies in eggs or digestive enzymes in corn, the potential of transgenic animals and plants for the cheap and efficient production of biopharmaceuticals is huge and could reap sales of more than $12bn (€10bn) by 2012 according to market research firm Kalorama.

    The cost of producing biopharmaceuticals in bacterial or mammalian cell culture bioreactor facilities or through cell lines is much higher than in transgenic technology and with expression levels of 2 to 10 grams of recombinant protein per litre of milk being readily achievable in transgenic livestock, as opposed to highly optimised cell cultures that can typically generate 0.2 to 1 grams per litre of culture medium, scale is also an important benefit of this new technology, according to the Kalorama report.

    Atryn, the new drug that has just been given the nod, is an anti-clotting agent and has been cleared for use in surgery in people with a rare congenital disease, antithrombin deficiency.

    Only one person in every 3,000 to 5,000 people suffer from the condition, making clinical studies hard to conduct and as a result, European regulators initially rejected the drug on the grounds that not enough surgical cases were brought before them – they got five out of the twelve requested – and the fact that results from patients treated in a compassionate use programme and at childbirth could not be accepted.

    However, on appeal, a reconsideration of the evidence to include the nine cases of women given ATryn in childbirth led to an EMEA backflip.

    “ATryn may be a specialised drug for a rare hereditary disease but getting approval of the first drug manufactured by an animal or plant is a real stepping stone,” said Newberry.

    “The decision clearly validates this new method as a viable way to express protiens and lower the capital required to produce large volumes of proteins."

    On receiving the good news US-based GTC received its first $1m milestone payment from LEO Pharma who the biotech firm partnered with to its develop and market the drug in Europe, Canada, and the Middle East.

    GTC is also due a $2m payment upon final marketing authorisation by the European Commission, expected in three months time.

    Upon approval, Atryn will be the only available antithrombin product that is not derived from the human blood supply and will also be the first antithrombin product approved for use in all 25 countries of the European Union (EU).

    At this stage the GTC is unsure when the product will hit the market: "We were surprised that the EMEA decision was turned around so quickly so it is now up to LEO to decide when they can launch the product," said Newberry.

    GTC will be responsible for ATryn production and in addition to sales and marketing, LEO is responsible for additional clinical development of ATryn in Europe.

    LEO has already begun development of Atryn as a potential treatment for another indication - disseminated intravascular coagulation (DIC) - an area of major unmet medical need, occurring in 220,000 severe sepsis cases in the EU each year, of which half are fatal.

    LEO has now requested scientific advice from the EMEA as the basis for the first planned clinical studies in DIC.

    Meanwhile, GTC is still looking for approval in the US and said it will use the results from both the completed study of hereditary deficient patients reviewed by the EMEA and GTC's ongoing pivotal phase III study to prepare a Biologics License Application (BLA) for the US Food and Drug Administration (FDA), which is planned for mid-2007.

    In addition to the ATryn program, GTC has in development a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine.

    Other firms active in the transgenic arena include Pharming, Hematech/Kirin Brewery and Avigenics.

    Dutch company Pharming is developing a drug for hereditary angioedema that is expressed in the milk of rabbits; US firm Hematech, owned by Japan's Kirin Brewery is focusing on human antibody-producing cows that will be used for the development of large quantities of polyclonal antibodies, which could form the basis of drugs for viral or bacterial infections and autoimmune disorders; while US-based Avigenics is pursuing avian transgenesis for treatments in oncology, infectious disease and autoimmune disease.

    As the “pharming” trend takes hold, the EMEA's landmark approval signals the beginning of a new era of drug treatments and potential big dollar revenues.
  21. [verwijderd] 22 juni 2006 16:20

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Silvergold schreef:

    ja, gaat prima zo,1,58 nu, is even 1,59 geweest.

    volume goed, mmmmmmmmmmmmmmmm
    volume blijft pover hoor! 134000 stuks, maar goed het is meer dan gisteren de hele dag.
    Jammer dat Nasdaq daalt juist wanneer GTCB begint te klimmen
27.049 Posts
Pagina: «« 1 ... 1340 1341 1342 1343 1344 ... 1353 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.017
AB InBev 2 5.496
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.645
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.644
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.751
Aedifica 3 916
Aegon 3.258 322.821
AFC Ajax 538 7.088
Affimed NV 2 6.296
ageas 5.844 109.891
Agfa-Gevaert 14 2.050
Ahold 3.538 74.335
Air France - KLM 1.025 35.043
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.792
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 243.150
AMG 971 133.318
AMS 3 73
Amsterdam Commodities 305 6.689
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 14.998
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.776
Arcelor Mittal 2.033 320.704
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.300
Aroundtown SA 1 219
Arrowhead Research 5 9.735
Ascencio 1 27
ASIT biotech 2 697
ASMI 4.108 39.096
ASML 1.766 107.157
ASR Nederland 21 4.484
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.667
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392